1Albers GW,Hart RG,Lutsep HL,et al.Supplement to the Guidelines for the management of transient ischmic attacks: a statement from the Ad Hoc Committee for the management of transient ischemic attacks,stroke council, America Heart Association[].Stroke.1999
2Hart KG,Harison MJ.Aspirin wars: the optimal dose of aspirin to prevent stroke[].Stroke.1996
3Feinberg WM,Albers GW,Barnett HJM,et al.Guideline for the management of transient ischemic attacks: from the Ad Hoc Committee on Guideline for the management of transient ischemic attacks of stroke council of the American Heart Association.AHA medical/scientific statement: special report[].Circulation.1994
4Diener HC,Cunba C,Forbes C,et al.European stroke prevention study 2: dipyridamole and acetylsalicylie acid in the secondary prevention of stroke[].Journal of the Neurological Sciences.1996
5International Stroke Trial Collaborative Group.The internation stroke trial(IST): A randomized trial of aspirin, subcutaneous heparin both, or neither among 19, 435 patients with acute ischemic stroke[].The Lancet.1997
6Schror K. New antiplatelet agents and the question of dual anti- platelet therapy. Internist ( Berl), 2012,53 ( 3 ) :351-356.
7Paraskevas KI, Mikhailidis DP, Roussas N, et al. Effect of anti- platelet agents, statins, and other drugs on vascular access patency rates . Angiology, 2012,53( 1 ) :5-8.
8Pamukcu B, Huber K, Lip GY. Antiplatelet therapy in athero- thrombotic cardiovascular diseases for primary and secondary pre- vention : A focus on old and new antiplatelet agents. Curt Pharm Des, 2012,18(6) :850-860.
9Yip S, Benavente O. Antiplatelet agents for stroke prevention. Neurotherapeutics, 2011,8 (3) :475-487.
